ShockWave Medical, Inc. (SWAV): Price and Financial Metrics

ShockWave Medical, Inc. (SWAV): $187.83

-6.81 (-3.50%)

POWR Rating

Component Grades














  • Growth is the dimension where SWAV ranks best; there it ranks ahead of 94.15% of US stocks.
  • The strongest trend for SWAV is in Momentum, which has been heading up over the past 177 days.
  • SWAV's current lowest rank is in the Stability metric (where it is better than 6% of US stocks).

SWAV Stock Summary

  • Price to trailing twelve month operating cash flow for SWAV is currently 81.68, higher than 95.18% of US stocks with positive operating cash flow.
  • Over the past twelve months, SWAV has reported earnings growth of -346.83%, putting it ahead of only 4.55% of US stocks in our set.
  • As for revenue growth, note that SWAV's revenue has grown 144.7% over the past 12 months; that beats the revenue growth of 94.35% of US companies in our set.
  • Stocks that are quantitatively similar to SWAV, based on their financial statements, market capitalization, and price volatility, are NICE, DV, YELP, CRCT, and SPSC.
  • SWAV's SEC filings can be seen here. And to visit SHOCKWAVE MEDICAL INC's official web site, go to

SWAV Valuation Summary

  • In comparison to the median Healthcare stock, SWAV's EV/EBIT ratio is 621.21% higher, now standing at 71.4.
  • SWAV's price/sales ratio has moved down 48.5 over the prior 47 months.

Below are key valuation metrics over time for SWAV.

Stock Date P/S P/B P/E EV/EBIT
SWAV 2023-01-20 15.2 18.4 74.2 71.4
SWAV 2023-01-19 14.7 17.8 72.0 69.3
SWAV 2023-01-18 15.2 18.4 74.3 71.5
SWAV 2023-01-17 16.2 19.5 79.0 76.1
SWAV 2023-01-13 17.0 20.5 82.9 79.9
SWAV 2023-01-12 16.8 20.3 82.2 79.2

SWAV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SWAV has a Quality Grade of D, ranking ahead of 16.69% of graded US stocks.
  • SWAV's asset turnover comes in at 0.474 -- ranking 102nd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows SWAV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.474 0.773 -0.306
2021-03-31 0.305 0.725 -0.488
2020-12-31 0.256 0.690 -0.552
2020-09-30 0.233 0.662 -0.751
2020-06-30 0.233 0.625 -0.695
2020-03-31 0.276 0.612 -0.565

SWAV Price Target

For more insight on analysts targets of SWAV, see our SWAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $210.67 Average Broker Recommendation 1.64 (Moderate Buy)

SWAV Stock Price Chart Interactive Chart >

Price chart for SWAV

SWAV Price/Volume Stats

Current price $187.83 52-week high $320.54
Prev. close $194.64 52-week low $113.36
Day low $185.59 Volume 231,000
Day high $193.67 Avg. volume 489,522
50-day MA $218.33 Dividend yield N/A
200-day MA $225.76 Market Cap 6.79B

ShockWave Medical, Inc. (SWAV) Company Bio

Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

SWAV Latest News Stream

Event/Time News Detail
Loading, please wait...

SWAV Latest Social Stream

Loading social stream, please wait...

View Full SWAV Social Stream

Latest SWAV News From Around the Web

Below are the latest news stories about SHOCKWAVE MEDICAL INC that investors may wish to consider to help them evaluate SWAV as an investment opportunity.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Yahoo | January 23, 2023

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

By Davit Kirakosyan

Yahoo | January 22, 2023

3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023

These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.

Yahoo | January 21, 2023

ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues

ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.

Yahoo | January 19, 2023

SWAV stock defended at BofA; says Neovasc “not a big risk” (NASDAQ:SWAV)

Bank of America reaffirmed its Buy rating on ShockWave Medical (SWAV) after its shares witnessed a sharp in reaction to a deal to acquire Neovasc (NVCN). Read the full story here.

Seeking Alpha | January 18, 2023

Read More 'SWAV' Stories Here

SWAV Price Returns

1-mo -9.48%
3-mo -34.02%
6-mo -11.82%
1-year 40.31%
3-year 328.15%
5-year N/A
YTD -8.65%
2022 15.30%
2021 71.93%
2020 136.16%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6634 seconds.